长药控股(300391) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥520,639,780.76, representing an increase of 88.36% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥12,705,374.70, up 54.47% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥7,533,729.99, an increase of 68.34%[3]. - Year-to-date revenue reached ¥1,818,276,737.67, reflecting a significant growth of 181.86% compared to the previous year[3]. - The company experienced a 181.86% increase in operating income primarily due to the acquisition of Changjiang Star in December 2020[8]. - Total operating revenue for the third quarter reached ¥1,818,276,737.67, a significant increase from ¥645,101,554.54 in the same period last year, representing a growth of approximately 181.5%[21]. - Net profit for the quarter was ¥190,605,005.24, a substantial rise from ¥140,209.88 year-over-year, reflecting a growth of approximately 135,500%[22]. - Earnings per share (EPS) for the quarter was ¥0.2760, compared to ¥0.0025 in the same quarter last year, marking an increase of 10,840%[23]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥185,215,404.74, showing a remarkable increase of 1,321.92%[3]. - Cash flow from operating activities was ¥1,480,917,576.25, significantly higher than ¥412,197,888.64 in the previous year, showing an increase of about 259.5%[25]. - The net cash flow from operating activities for Q3 2021 was ¥185,215,404.74, a significant improvement compared to a net outflow of ¥15,157,777.17 in Q3 2020[26]. - Total cash inflow from investment activities was ¥533,399,869.51, while cash outflow was ¥819,481,595.70, resulting in a net cash flow of -¥286,081,726.19 for the quarter[26]. - Cash inflow from financing activities totaled ¥601,714,504.83, with a net cash flow of ¥82,771,146.89 after outflows[27]. - The company reported a total cash and cash equivalents balance of ¥88,775,727.37 at the end of Q3 2021, down from ¥106,892,283.87 at the beginning of the quarter[27]. - The company received ¥362,580,000.00 in cash from borrowings during the quarter, compared to ¥115,700,000.00 in the same period last year[27]. - Cash received from other financing activities amounted to ¥239,134,504.83, an increase from ¥49,878,674.25 year-over-year[27]. - The company paid ¥480,463,386.53 in debt repayments during Q3 2021, compared to ¥185,000,000.00 in Q3 2020[27]. - The total cash outflow for operating activities was ¥1,368,183,908.26, compared to ¥455,574,533.80 in the previous year[26]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,279,064,810.47, a decrease of 8.63% from the end of the previous year[3]. - The company's current assets totaled approximately RMB 2.23 billion, compared to RMB 2.12 billion at the end of 2020, indicating an increase of about 5.2%[17]. - The total liabilities decreased from ¥3,233,554,499.76 to ¥2,638,239,341.32, a reduction of approximately 18.4%[22]. - The total equity attributable to shareholders of the parent company increased from ¥776,694,642.74 to ¥874,133,348.55, reflecting a growth of about 12.5%[22]. - The company reported a total current liability of approximately RMB 2.14 billion, down from RMB 2.63 billion, indicating a decrease of about 18.4%[18]. - The non-current assets totaled approximately RMB 2.05 billion, down from RMB 2.56 billion, indicating a decrease of about 20.0%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,185[10]. - The company completed the acquisition of a 52.7535% stake in Hubei Changjiang Star Pharmaceutical Co., with a total transaction value of approximately RMB 1.41 billion[15]. - The company plans to raise up to RMB 140 million through a simplified procedure for issuing shares to specific targets[15]. Operational Changes - The construction site for the pharmaceutical research and development center has been changed from Shenzhen to Gong'an County, Hubei Province[15]. - The company reported a significant increase in accounts receivable financing by 50.57% due to an increase in receivables[8]. - The company recorded a 465.39% increase in asset disposal gains, amounting to ¥3,147,878.67, due to the disposal of properties and land[9]. Other Financial Metrics - The weighted average return on equity was 1.46% for the current period, compared to 1.09% in the same period last year[3]. - The company reported a credit impairment loss of ¥-37,317,188.90, compared to ¥-2,012,163.15 in the previous year, indicating a deterioration in credit quality[22]. - The company’s deferred income tax liabilities decreased from ¥10,946,186.91 to ¥9,248,506.31, a decline of approximately 15.5%[22]. - The total comprehensive income for the quarter was ¥190,597,398.24, compared to a loss of ¥-5,681,553.49 in the same quarter last year, indicating a significant turnaround[23]. Audit and Compliance - The company did not undergo an audit for the Q3 2021 report[28]. - The report indicates that the company has not applied the new leasing standards for the current year[28].